Pharmaceutical Business Review
Anonymous User | Login

GTx Initiates Phase I Prostate Cancer Trial

Published: 07-Jul-2009

To establish proof of the ability of GTx-758 to reduce testosterone

GTx has initiated Phase I multiple ascending dose clinical trial evaluating GTx-758, an oral LH inhibitor for first line treatment of advanced prostate cancer. A Phase I single ascending dose clinical trial in 96 subjects was successfully completed in June.

In Phase I single ascending dose clinical trial, GTx-758 was well tolerated. GTx-758 demonstrated a pharmacokinetic profile compatible with once daily oral dosing and systemic exposures increasing with dose.

The ongoing Phase I multiple ascending dose clinical trial is an open label, single center study of five dose groups of GTx-758, with ten healthy male subjects per group each receiving doses for 10 days. The study will evaluate the safety, tolerability and pharmacokinetic profile of GTx-758.

In addition, testosterone and other hormones will be measured to assess the activity of GTx-758 on hormones secreted by the pituitary, hypothalamus, and adrenal glands.

Mitchell Steiner, CEO of GTx, said: “In this clinical trial, we expect to establish proof of the ability of GTx-758 to reduce testosterone, which is the endpoint required for primary androgen deprivation therapy clinical trials.”

GTx expects to complete this Phase I multiple ascending dose clinical trial in the fourth quarter.

Mail sent successfully

Tell your friend about this article


Please enter a valid email address

Please enter your name

Please enter the mail body


Your Name: *
Your Email: *
Friend's Email: *
Email Body: *
 

Suppliers To This Sector

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Almac

Drug Development Solutions ...

STARLIMS

Benefits for Life Science Labs ...

Parenteral Drug Association (PDA)

Pharmaceutical Information and Education Services ...

Burkert Fluid Control Systems

Fluid and Gas Control Systems ...

IMCOR

LIMS and Laboratory Informatics Consultancy ...

Umicore Precious Metals Chemistry

Chemicals and Catalysts for Industrial Applications ...

White Papers

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

CaseBase Management

BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...

SafetyBase Interchange

BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...

ClinicalBase Trial

BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...

Reliable Prediction of White Plasma Levels

Our kinetics & metabolism experts can help you select and further develop your candidate d ...

Kinetics and Metabolism

Our kinetics & metabolism experts can help you select and further develop your candidate d ...

Drug Safety Evaluation

Our kinetics & metabolism experts can help you select and further develop your candidate d ...

Related Companies

GTx, Inc.

GTx, Inc. (GTX) is a biopharmaceutical company, focused on the discovery, development, ...

AstraZeneca PLC

AstraZeneca PLC (AstraZeneca) is a leading pharmaceuticals company engaged in the desig ...

OSI Pharmaceuticals, Inc.

OSI Pharmaceuticals, Inc. (OSI) is a biopharmaceutical company focused on the discovery ...

Merck & Co., Inc.

Merck & Co., Inc. (Merck) is a global research-driven pharmaceutical company engaged in ...

Amgen Inc.

Amgen Inc. (Amgen) is a biotechnology company that is focused on the discovery, develo ...

Suppliers Product News

Almac Completes Phase One of Its Expansion Plan to Pharma Services Facilities

New $15m facility will "meet growing business need for its integrated product development and commercial services."

Free Newsletter Sign-up

Sign up, and we will send you a free Pharmaceutical report on “ Combination Products – Evolution of the Medical Equipment Industry” from GlobalData worth $750

Please enter a valid email address